paper-–-jnl-of-analytical-toxicology:-“conventional-drug-testing-cannot-reliably-distinguish-between-illicit-cannabis-and-legal-hemp-derived-product-use,-and-a-positive-urine-Δ9-thc-test-may-result-from-low-doses-that-do-not-produce-intoxication-or-impairment.”-|-cannabis-law-report-|-where-to-order-skittles-moonrock-online

Paper – Jnl of Analytical Toxicology: “Conventional drug testing cannot reliably distinguish between illicit cannabis and legal hemp-derived product use, and a positive urine Δ9-THC test may result from low doses that do not produce intoxication or impairment.” | Cannabis Law Report | Where to order Skittles Moonrock online

Learn how to buy Skittles Moonrock online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

As always a big thanks to Lex Pelger for the heads up on this one

Conventional drug testing cannot reliably distinguish between illicit cannabis and legal hemp-derived product use, and a positive urine Δ9-THC test may result from low doses that do not produce intoxication or impairment.

The acute and chronic pharmacokinetics and pharmacodynamics of oral cannabidiol with and without low doses of delta-9-tetrahydrocannabinol Open Access

Abstract

Hemp products [cannabis with ≤0.3% Δ9-tetrahydrocannabinol (Δ9-THC)] are federally legal, but few controlled experiments have explored drug test results, pharmacokinetics, or pharmacodynamics. Healthy adults (n = 60) self-administered 1.5 mL medium-chain triglyceride (MCT) oil containing 100 mg cannabidiol (CBD) and either 0, 0.5, 1, 2, 2.8, or 3.7 mg Δ9-THC (n = 10 per group). The study included an 8-hour acute dose laboratory session (Phase 1), a 14-day outpatient drug exposure period with twice daily dosing (Phase 2) and a 7-day washout period (Phase 3). Measures including urine, blood, subjective drug effects, and cognitive and psychomotor performance were assessed repeatedly throughout the experiment. At least one participant receiving Δ9-THC doses of 1.0 mg or greater had at least 1 positive urine drug test (Δ9-THC-COOH immunoassay screen ≥50 ng/mL and LC-MS/MS confirmation ≥15 ng/mL) during Phase 1 and the number of positive urine samples increased with Δ9-THC dose. Positive urine drug tests were observed during the Phase 2 outpatient drug exposure period from at least one participant in each dose condition that contained any amount of Δ9-THC. One urine specimen in the CBD only dose condition tested positive during Phase 2. Two positive urine samples were observed after the 1-week washout (Day 21). Blood concentrations of Δ9-THC were very low in all dose conditions, and there were no significant differences between the CBD only dose group and Δ9-THC-containing dose groups on any pharmacodynamic outcome. Individuals subject to drug testing should recognize that hemp products contain detectable amounts of Δ9-THC. Conventional drug testing cannot reliably distinguish between illicit cannabis and legal hemp-derived product use, and a positive urine Δ9-THC test may result from low doses that do not produce intoxication or impairment.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

New Purchase

Somebody from [variable_2] has just bought [variable_3] [amount] minutes ago.